Preview

Safety and Risk of Pharmacotherapy

Advanced search

Aggressive Pharmacotherapy in Reproductive Medicine. Pregnancy and Medicines (Author’s Perspective)

https://doi.org/10.30895/2312-7821-2024-434

Abstract

The article discusses the issues of polypharmacy and unjustified prescribing in pregnant women. The author— Honoured Scientist of the Russian Federation, Corresponding Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Full Professor, and Head of the Department for Obstetrics and Gynaecology with a Course on Perinatology at the Institute of Medicine of the Peoples’ Friendship University of Russia named after Patrice Lumumba, Viktor E. Radzinskiy — questions the established practice of unnecessary hospitalisation of pregnant women without clinical indications and prescribing them numerous medicinal products, including antimicrobials, hormones, and antispasmodics. In most cases, pregnancy does not require medical intervention. The widespread use of progestogens in patients with threatened miscarriage lacks an evidence base. Antispasmodics, such as papaverine, are ineffective in threatened preterm labour. The author calls for a rational approach to prescribing medicinal products to pregnant women based on current clinical practice guidelines and the “do no harm” maxim. Viktor E. RADZINSKIY emphasises the need to follow clinical protocols and ensure physicians are informed about the evidence for the use of medicinal products in pregnancy to prevent polypharmacy and adverse consequences.

About the Author

V. E. Radzinskiy
Peoples’ Friendship University of Russia named after Patrice Lumumba
Russian Federation

Viktor E. Radzinskiy, Corresponding Member of the Russian Academy of Sciences, Dr. Sci. (Med.), Professor

6 Miklukho-Maklay St., Moscow 117198



References

1. Radzinskiy VE. Obstetric aggression, v. 2.0. Moscow: Publishing House of Status Praesens; 2017 (In Russ.). EDN: LBPMMI

2. Radzinskiy VE. Drug provision for clinical protocols. Obstetrics and gynecology. Moscow: GEOTAR-Media; 2023 (In Russ.). EDN: CUMGYO

3. Radzinskiy VE, Knyazev SA, Kostin IN, Apresyan SV, Artymuk NV, Belokrinitskaya TE, et al. Predictive obstetrics. Moscow: Media Bureau Status Praesens; 2021 (In Russ.). EDN: PHHUEF

4. Dante G, Vaccaro V, Facchinetti F. Use of progestagens during early pregnancy. Facts Views Vis Obgyn. 2013;5(1):66–71. PMID: 24753930

5. Coomarasamy A, Devall AJ, Brosens JJ, Quenby S, Stephenson MD, Sierra S, et al. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence. Am J Obstet Gynecol. 2020;223(2):167–76. https://doi.org/10.1016/j.ajog.2019.12.006

6. Sovijit WN, Sovijit WE, Pu S, Usuda K, Inoue R, Watanabe G, et al. Ovarian progesterone suppresses depression and anxiety-like behaviors by increasing the Lactobacillus population of gut microbiota in ovariectomized mice. Neurosci Res. 2021;168:76–82. https://doi.org/10.1016/j.neures.2019.04.005

7.


Supplementary files

Review

For citations:


Radzinskiy V.E. Aggressive Pharmacotherapy in Reproductive Medicine. Pregnancy and Medicines (Author’s Perspective). Safety and Risk of Pharmacotherapy. 2024;12(3):247-252. (In Russ.) https://doi.org/10.30895/2312-7821-2024-434

Views: 1221


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2312-7821 (Print)
ISSN 2619-1164 (Online)